< 2004 News Listings Tercica, Inc. Names Thomas H. Silberg Chief Operating Officer SOUTH SAN FRANCISCO, CA April 21, 2004 Tercica, Inc. (Nasdaq: TRCA) announced today that it has appointed Thomas H. Silberg to the newly created position of Chief Operating Officer, reporting to John A. Scarlett, M.D., President and Chief Executive Officer. Effective immediately, Silberg will be responsible for overseeing Tercica's Manufacturing and Commercial operations, as well as its Business Development and Project Management functions. Silberg brings more than 32 years of pharmaceutical and biotechnology industry experience from Hoffmann-La Roche Inc. (Roche) and Ligand Pharmaceuticals, Inc., where he worked most recently as Executive Vice President and Chief Operating Officer responsible for all International and US Commercial and Technical Operations, including sales and marketing, medical affairs, as well as technical and supply operations. During his tenure at Ligand, Silberg led the restructuring of the company's commercial operations in order to optimize the roll out of key products and to set the stage for improved revenue growth. Prior to working at Ligand, Silberg served from 1972 to 2000 at Roche in positions of increasing responsibility, including sales, sales management and market research, and then served for 12 years in business and operations management. "Mr. Silberg brings a wealth of experience and track record of success in pharmaceutical operations and commercialization to Tercica," said Scarlett. "His depth of experience will be critical to us as we prepare to file our NDA in early 2005 for recombinant human insulin-like growth factor-1. In particular, we expect Mr. Silberg to play a key role in developing the broad commercial infrastructure necessary for a successful product launch. We welcome him to our team." At Roche, from 1988 to 1994, Silberg was Vice President, Health Systems Management, a strategic business unit within Roche Pharmaceuticals that he was instrumental in creating, positioning and developing in order to address the changing U.S. healthcare marketplace. In 1994, Silberg was named Vice President, Business Operations of Roche Pharmaceuticals, a position in which he ultimately was responsible for approximately $1 billion in revenue and a commercial organization of 650 employees. His functional responsibilities in this role also included all general management activities relating to the sales and marketing of the entire Roche product line, including Rocephin, Roche's leading injectable antibiotic product in a 26-state geographic area. During this time, Roche was ranked the number one hospital pharmaceutical company in the U.S. Silberg earned his Bachelors of Science degree in Marketing/Advertising from the University of Minnesota in 1972. About Tercica Tercica is a biopharmaceutical company focused on the development and commercialization of rhIGF-1 for the treatment of short stature, diabetes and other endocrine system disorders. Tercica's initial target indications include Insulin-like Growth Factor-1 Deficiency (IGFD), including Severe Pediatric IGFD, Pediatric IGFD and Adult IGFD. In addition, the company is pursuing clinical studies of rhIGF-1 as a treatment for Diabetes, including Type 2 diabetes with Severe Insulin Resistance and Type A diabetes. Safe Harbor Statement This press release contains forward-looking statements regarding Tercica's development and commercialization of treatments for certain forms of extreme insulin resistance and other types of diabetes, short stature and other endocrine system disorders, including statements regarding Tercica's filing of an NDA in early 2005 for recombinant human insulin-like growth factor-1, and statements regarding the development of the commercial infrastructure necessary for a successful product launch. The forward-looking statements are subject to risks and uncertainties that could cause actual events to differ materially from those projec> ted, including those risks and uncertainties listed in the Form S-1, as amended, relating to Tercica's initial public offering, which was declared effective by the SEC on March 16, 2004. Any statements by persons outside Tercica speculating on the subject matter of this press release, or any other aspects of the company's business, will not be based on internal company information and should be assessed accordingly by investors. Contact: Kimberly Kraemer Senior Director, Corporate Communications and Investor Relations Phone: (650) 624-4949
	Copyright ©2007 Rho Capital Partners, Inc.